Foamix Pharmaceuticals Ltd. Operating Cash Flow
Foamix Pharmaceuticals Ltd. reported Operating Cash Flow of -$73.39 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2020-03-12
- Foamix Pharmaceuticals Ltd. net cash provided by (used in) operating activities for the quarter ending 2019-12-31 was -$22.25M.
- Foamix Pharmaceuticals Ltd. net cash provided by (used in) operating activities for the quarter ending 2019-09-30 was -$21.79M.
- Foamix Pharmaceuticals Ltd. net cash provided by (used in) operating activities for the quarter ending 2019-06-30 was -$12.72M.
- Foamix Pharmaceuticals Ltd. net cash provided by (used in) operating activities for the quarter ending 2019-03-31 was -$16.64M.
- Foamix Pharmaceuticals Ltd. net cash provided by (used in) operating activities for fiscal 2019 was -$73.39M.
- Foamix Pharmaceuticals Ltd. net cash provided by (used in) operating activities for fiscal 2018 was -$68.66M.
- Foamix Pharmaceuticals Ltd. net cash provided by (used in) operating activities for fiscal 2017 was -$53.18M.
- Foamix Pharmaceuticals Ltd. net cash provided by (used in) operating activities for fiscal 2016 was -$27.37M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$22.25M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$44.03M derived: sum of 2 quarters · filed 2020-03-12 | -$56.75M derived: sum of 3 quarters · filed 2020-03-12 | -$73.39M 10-K · filed 2020-03-12 |
| 2019-09-30 | -$21.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$34.51M derived: sum of 2 quarters · filed 2019-11-12 | -$51.15M 10-Q · filed 2019-11-12 | -$62.05M derived: sum of 4 quarters · filed 2020-03-12 |
| 2019-06-30 | -$12.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$29.36M 10-Q · filed 2019-08-07 | -$40.26M derived: sum of 3 quarters · filed 2020-03-12 | -$61.50M derived: sum of 4 quarters · filed 2020-03-12 |
| 2019-03-31 | -$16.64M 10-Q · filed 2019-05-07 | -$27.54M derived: sum of 2 quarters · filed 2020-03-12 | -$48.78M derived: sum of 3 quarters · filed 2020-03-12 | -$62.11M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-12-31 | -$10.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$32.14M derived: sum of 2 quarters · filed 2020-03-12 | -$45.47M derived: sum of 3 quarters · filed 2020-03-12 | -$68.66M 10-K · filed 2020-03-12 |
| 2018-09-30 | -$21.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$34.57M derived: sum of 2 quarters · filed 2019-11-12 | -$57.77M 10-Q · filed 2019-11-12 | -$70.40M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | -$13.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$36.52M 10-Q · filed 2019-08-07 | -$49.16M derived: sum of 3 quarters · filed 2020-03-12 | -$68.92M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | -$23.19M 10-Q · filed 2019-05-07 | -$35.83M derived: sum of 2 quarters · filed 2020-03-12 | -$55.59M derived: sum of 3 quarters · filed 2020-03-12 | -$64.32M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | -$12.63M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$32.39M derived: sum of 2 quarters · filed 2020-03-12 | -$41.12M derived: sum of 3 quarters · filed 2020-03-12 | -$53.18M 10-K · filed 2020-03-12 |
| 2017-09-30 | -$19.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$28.49M derived: sum of 2 quarters · filed 2018-11-07 | -$40.54M 10-Q · filed 2018-11-07 | |
| 2017-06-30 | -$8.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | -$20.78M 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | -$12.05M 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | -$27.37M 10-K · filed 2019-02-28 | |||
| 2015-12-31 | -$12.50M 10-K · filed 2018-03-01 |